A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients
about
Improving cancer immunotherapy by targeting the STATe of MDSCsFocus on Nivolumab in NSCLCMyeloid-derived suppressor cells in the tumor microenvironment: expect the unexpectedLectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients.The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy.Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy.Monocytic myeloid-derived suppressor cells as a potent suppressor of tumor immunity in non-small cell lung cancer.Increasing the efficacy of radiotherapy by modulating the CCR2/CCR5 chemokine axes.CXCL10 and CCL2 mRNA expression in monocytes is inversely correlated with the HLA-DR lower fraction of monocytes in patients with renal cell carcinoma.A clinical and biological perspective of human myeloid-derived suppressor cells in cancer.Analysis of the prognostic role of an immune checkpoint score in resected non-small cell lung cancer patients.Establishing High Dimensional Immune Signatures from Peripheral Blood via Mass Cytometry in a Discovery Cohort of Stage IV Melanoma Patients.Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation.Myeloid-Derived Suppressor Cells.Phenotypically resembling myeloid derived suppressor cells are increased in children with HIV and exposed/infected with Mycobacterium tuberculosis.The lymphocyte-monocyte ratio predicts tumor response and survival in patients with locally advanced esophageal cancer who received definitive chemoradiotherapy.PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors.Immunotherapy of cancer: targeting cancer during active disease or during dormancy?Use of antigen-primed dendritic cells for inducing antitumor immune responses in vitro in patients with non-small cell lung cancer.Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system.Mesenchymal stromal cells enhance the suppressive effects ofmyeloid-derived suppressor cells of multiple myeloma.Myeloid-derived suppressor cells in ovarian cancer: friend or foe?Oncolytic influenza virus infection restores immunocompetence of lung tumor-associated alveolar macrophages.Immunosuppressive Role of Myeloid-Derived Suppressor Cells and Therapeutic Targeting in Lung Cancer.Treating the Intestine with Oral ApoA-I Mimetic Tg6F Reduces Tumor Burden in Mouse Models of Metastatic Lung Cancer.A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomyPrognostic role of pretreatment circulating MDSCs in patients with solid malignancies: A meta-analysis of 40 studiesDiamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy
P2860
Q28066797-D019F643-F970-41F9-9241-2D30E0F87E67Q28073759-1498F65F-AFFD-4AE0-9B1E-486DC2621268Q28084627-86049360-2177-40B7-9E2B-5CD12542C7A5Q33564156-376936FA-51C8-4054-9520-EBBAA8B3EA0FQ33660069-8F8C82B2-B485-4940-A1F7-AA99B74A0872Q37559326-E60CF29B-A3B4-4848-8163-801026B7B34CQ37581919-63AF959D-5C37-4727-818A-56C4D5DFE84DQ37699273-C3EDE0CA-D6CB-422B-9FDD-8F72EE79C480Q38719748-2674D1E1-2EE1-4697-96A4-9ABF5A4A0640Q38847251-1E333347-FE32-4803-A497-F72CDEF31F74Q38961444-15AF345F-EB78-4A50-9FF9-D8D82DD4FE12Q39093439-78D0A8CD-DFB3-4B60-A585-EB48506A52D0Q39321597-CEDFFD90-ABC4-4081-8E42-033081FBEF2EQ40385399-B3832061-B56F-45AA-B6AF-A081D3D9BE0DQ40445818-825AA022-FF7A-4508-A0D3-5FEA4A68C827Q42161730-0CD590B0-990E-4726-8110-25575CCB5CBBQ47120629-792970CD-DEC9-4007-8CEC-477355E21924Q47404669-58F48550-A627-473D-A899-0B84D5D8D345Q47729557-C4FFF083-EA8F-4FA2-AD1B-21CEA62991F1Q49334976-9DCF1CE5-95C0-4AD7-B040-B4C40BC63DADQ50070316-6441395D-CCEF-411A-90A1-DEAEDDDD8EEAQ51094108-2C342DA9-838E-4ED4-AEC5-C23D4AD239F8Q52689050-336D6534-5AB5-43C9-84DB-5C13CFF2CC29Q53688637-60B3819E-CF6E-43D1-ABAB-E1360C3827BBQ54918600-23EC0A4C-E6E8-410F-8D16-323225102E09Q55222132-4F45409E-C116-4784-96E0-FD3099393CBCQ57038254-0037AD8F-1E59-4205-A490-5BD520CF345AQ57138311-C1387BAA-A3DE-4A30-AD45-85344A258176Q57817490-F2F661D7-4BA0-48F8-9712-5440582DE8FD
P2860
A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A circulating subpopulation of ...... non-small lung cancer patients
@ast
A circulating subpopulation of ...... non-small lung cancer patients
@en
A circulating subpopulation of ...... non-small lung cancer patients
@nl
type
label
A circulating subpopulation of ...... non-small lung cancer patients
@ast
A circulating subpopulation of ...... non-small lung cancer patients
@en
A circulating subpopulation of ...... non-small lung cancer patients
@nl
prefLabel
A circulating subpopulation of ...... non-small lung cancer patients
@ast
A circulating subpopulation of ...... non-small lung cancer patients
@en
A circulating subpopulation of ...... non-small lung cancer patients
@nl
P2093
P2860
P50
P356
P1476
A circulating subpopulation of ...... non-small lung cancer patients
@en
P2093
Athanasios Kotsakis
Dimitris Mavroudis
Eirini Skalidaki
Marianthi Gioulbasani
P2860
P304
P356
10.1155/2014/659294
P577
2014-11-11T00:00:00Z